About US
Contact us
-
Pfizer’s takeover bid for AstraZeneca raises concerns in UKPfizer's takeover bid of AstraZeneca has raised concerns regarding the company's commitment to research and development, as well as potential job losses in UK drug research. Pfizer has said that toge2014/5/9
-
Bayer to acquire Merck’s consumer care business for $14.2bnGerman chemical and pharmaceutical company Bayer has entered into a definitive agreement to acquire the consumer care business of US-based Merck for $14.2bn. Under the terms of the agreement, Bayer w2014/5/8
-
AstraZeneca obtains FDA approval for hypertriglyceridaemia drugAstraZeneca has obtained approval from the US Food and Drug Administration (FDA) for Epanova (omega-3-carboxylic acids) for treatment of adults with severe hypertriglyceridaemia. Epanova is designed2014/5/8
-
European Commission approves Pierre Fabre’s Hemangiol for infantile hemangioma treatmentPierre Fabre Dermatologie Laboratories has received paediatric use marketing authorisation from the European Commission for Hemangiol (propranolol), indicated for treatment of proliferating infantile2014/5/7
-
Teva’s Synribo for injection receives FDA approval for home administrationTeva Pharmaceutical has obtained US Food and Drug Administration (FDA) approval for Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration for patients2014/5/7
-
Merck and Endocyte Announce Independen​t DSMB Recommends Vintafolid​e PROCEED Phase III Trial be StoppedMerck(known as MSD outside the US and Canada) and Endocyte, Inc. haveannounced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has completed a pre-specified, interim futility analysi2014/5/6
-
Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in ObesitySecond Genome announced has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic2014/5/6
-
Otsuka's tuberculosis drug Deltyba secures marketing approval in EUJapan-based Otsuka Pharmaceutical has received marketing authorisation from the European Commission for Deltyba (delamanid) to use as part of an appropriate combination regimen for pulmonary multidrug2014/5/5
-
Allergan's Botox gets positive opinion from Irish Medicines BoardAllergan has received a positive opinion for Botox (Botulinum Toxin Type A) from the Irish Medicines Board serving as reference member state in the mutual recognition procedure (MRP) for treatment of2014/5/5
-
GSK's Incruse Ellipta gets FDA approval to treat airflow obstruction in COPD patientsGlaxoSmithKline (GSK) has received US Food and Drug Administration (FDA) approval for Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the once-daily, maintenance treatment of airflo2014/5/4